|

T-cell Receptor-engineered T-cells Clinical Trials

1 actively recruiting trial across 1 location

Also known as: AFNT-111, FH-A11KRASG12V-TCR, T-cell Receptor-engineered T Cells, T-cell Receptor-engineered T-lymphocytes, TCR T Cells +3 more

Pipeline

Phase 1: 1

Top Sponsors

  • Fred Hutchinson Cancer Center1

Indications

  • Metastatic Malignant Solid Neoplasm1
  • Cancer1

Seattle, Washington1 trial

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations

Fred Hutch/University of Washington Cancer Consortium

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.